To report an adverse event or product quality issue, please email us at reportnow@argenx.com or call us at 1-833-274-9411.
©2026 argenx | Disclaimer | Privacy Policy | Regulations | U.S. Supplemental Privacy Notice
Pursuing Uncharted Pathways
We’re helping accelerate innovation to bring hope to those living with long-overlooked diseases. Using our unique platform technologies, our scientists are working to turn promise into reality.
SIMPLE Antibody™ Platform
Unlock Novel and Complex Targets
The SIMPLE Antibody™ platform helps identify unconventional disease targets. It sources V regions from the immune systems of outbred llamas, which naturally produce highly diverse antibodies with strong similarity to human antibodies. The diversity allows our scientists to identify antibody candidates often missed by traditional discovery methods.
By combining llama-derived V regions with fully human Fc regions, our team creates a library of human-like antibodies that can be tested across multiple epitopes to find the right balance of potency, safety, and species cross-reactivity. This enables a more efficient discovery process and accelerates early-stage development.
Fc Engineering
Adjusting Immune Response for a More Precise Patient Impact
We enhance antibody performance through our Fc engineering technologies, including NHANCE®, ABDEG™, and POTELLIGENT®. These tools allow precise control over how antibodies interact with the immune system, improving half-life, effector function, and tissue targeting.
By adjusting the Fc region, we can tailor an antibody’s immune activity to match the specific needs of each therapeutic program. This precision engineering supports safer, more effective treatments across a wide range of autoimmune and rare diseases.
From Discovery to Development
Our team integrates the SIMPLE Antibody™ and Fc engineering platforms across the full development process, working closely with partners to accelerate innovation. External scientists and organizations contribute novel disease targets or biological insights, and we apply our discovery and engineering expertise to design optimized antibody candidates.
Together, these partnerships move antibody concepts from early discovery to clinical development. We’re translating groundbreaking science into potential new therapies for patients.
Discover
Collaborators bring deep mechanistic understanding of disease biology, targets, and pathways
Design
SIMPLE Antibody™ platform enables argenx to generate antibodies that recognize disease targets
Co-Create
Proprietary technologies allow argenx to optimize and engineer antibodies for first-in-human (FIH)
Advance
Together, these collaborations push optimized antibodies into clinical development
Explore More
At argenx, every piece of the innovation story connects. See where it leads next.
Co-Creation in Action
See what happens when our team takes promising leaps alongside leading scientists, physicians, and researchers.
Publications
Peer-reviewed publications that reflect our range of immunology innovation.
Case Studies
Discover the science and stories of how we’re helping expand possibilities in immunology.
